Andrea Cocci1, Fabrizio Di Maida2, Giorgio Ivan Russo3, Paolo Capogrosso4, Lotti Francesco5, Michele Rizzo6, Marina Di Mauro3, Andrea Salonia4, Gianmartin Cito1, Marco Falcone7, Andrea Romano1, Gaia Polloni8, Juan Ignacio Martinez-Salamanca9, Esaù Fernández-Pascual9, Andrea Minervini1, Nicola Mondaini10. 1. Department of Urology, Careggi Hospital, University of Florence, Viale S. Luca, 50134, Florence, FI, Italy. 2. Department of Urology, Careggi Hospital, University of Florence, Viale S. Luca, 50134, Florence, FI, Italy. fabrizio.dimaida@unifi.it. 3. Urology Section, Department of Surgery, University of Catania, Catania, Italy. 4. Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. 5. Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy. 6. Department of Urology, University of Trieste, Trieste, Italy. 7. Urology Clinic, A.O.U. Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy. 8. Psychosexuologist, Como, Italy. 9. Department of Urology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain. 10. Andrology Center, Villa Donatello Hospital, Florence, Italy.
Abstract
BACKGROUND AND OBJECTIVE: Plaque formation ordinarily takes place in the acute phase of Peyronie's disease. There is no unanimous consent regarding the management of the acute phase of Peyronie's disease. The objective of this study was to evaluate the advantages of using a single intralesional injection of collagenase Clostridium histolyticum in patients with the active phase of Peyronie's disease and to assess its effect on disease progression by reducing penile curvature and ameliorating pain during sexual intercourse. METHODS: Sexually active men aged older than 18 years with the acute phase of Peyronie's disease were enrolled. All patients received treatment with a single intralesional injection of collagenase Clostridium histolyticum. The primary outcome of the study was the change in penile curvature after treatment while secondary outcomes were the change in sexual function (International Index of Erectile Function [IIEF-5]) and in the Peyronie Disease Questionnaire (PDQ) and its sub-scores, PDQ-PS (psychological symptoms), PDQ-PP (penile pain) and PDQ-BD (bother disease). RESULTS: Overall, 74 patients were enrolled. Mean penile curvature at baseline was 41.1° ± 12.2°. The mean changes before and at the 3-month evaluation in terms of penile curvature, Visual Analog Scale score at rest, and Visual Analog Scale score during intercourse were - 19.3 ± 8.4 (p < 0.0001), - 0.8 ± 1.1 (p < 0.0001) and - 3.8 ± 0.9 (p < 0.0001) with the benefit persisting also after 6 months. Moreover, improvements of mean IIEF-5 score (1.1 ± 0.9, p = 0.03; 0.9 ± 0.5, p = 0.02), PDQ-PS (- 2.7 ± 2.2; - 2.5 ± 2.0, p = 0.01), PDQ-PP (- 1.2 ± 1.6; - 1.1 ± 1.2, p = 0.02) and PDQ-BD (- 3.8 ± 3.4; - 3.5 ± 3.1, p = 0.001) were observed 3 and 6 months after the end of treatment, respectively. At the multivariable regression analysis, the time since disease onset (modelled with non-linear terms) and baseline curvature were independently associated with the degree of curvature improvement (coefficient: 0.30; 95% confidence interval 0.16-0.44) after a single intralesional injection (all p < 0.03). CONCLUSIONS: Although intralesional therapy with collagenase Clostridium histolyticum is not yet indicated for the acute phase of Peyronie's disease, these preliminary results suggest the effectiveness of this minimally invasive option by improving penile curvature and IIEF-5 and PDQ scores.
BACKGROUND AND OBJECTIVE: Plaque formation ordinarily takes place in the acute phase of Peyronie's disease. There is no unanimous consent regarding the management of the acute phase of Peyronie's disease. The objective of this study was to evaluate the advantages of using a single intralesional injection of collagenase Clostridium histolyticum in patients with the active phase of Peyronie's disease and to assess its effect on disease progression by reducing penile curvature and ameliorating pain during sexual intercourse. METHODS: Sexually active men aged older than 18 years with the acute phase of Peyronie's disease were enrolled. All patients received treatment with a single intralesional injection of collagenase Clostridium histolyticum. The primary outcome of the study was the change in penile curvature after treatment while secondary outcomes were the change in sexual function (International Index of Erectile Function [IIEF-5]) and in the Peyronie Disease Questionnaire (PDQ) and its sub-scores, PDQ-PS (psychological symptoms), PDQ-PP (penile pain) and PDQ-BD (bother disease). RESULTS: Overall, 74 patients were enrolled. Mean penile curvature at baseline was 41.1° ± 12.2°. The mean changes before and at the 3-month evaluation in terms of penile curvature, Visual Analog Scale score at rest, and Visual Analog Scale score during intercourse were - 19.3 ± 8.4 (p < 0.0001), - 0.8 ± 1.1 (p < 0.0001) and - 3.8 ± 0.9 (p < 0.0001) with the benefit persisting also after 6 months. Moreover, improvements of mean IIEF-5 score (1.1 ± 0.9, p = 0.03; 0.9 ± 0.5, p = 0.02), PDQ-PS (- 2.7 ± 2.2; - 2.5 ± 2.0, p = 0.01), PDQ-PP (- 1.2 ± 1.6; - 1.1 ± 1.2, p = 0.02) and PDQ-BD (- 3.8 ± 3.4; - 3.5 ± 3.1, p = 0.001) were observed 3 and 6 months after the end of treatment, respectively. At the multivariable regression analysis, the time since disease onset (modelled with non-linear terms) and baseline curvature were independently associated with the degree of curvature improvement (coefficient: 0.30; 95% confidence interval 0.16-0.44) after a single intralesional injection (all p < 0.03). CONCLUSIONS: Although intralesional therapy with collagenase Clostridium histolyticum is not yet indicated for the acute phase of Peyronie's disease, these preliminary results suggest the effectiveness of this minimally invasive option by improving penile curvature and IIEF-5 and PDQ scores.
Authors: Scott C Brimley; Faysal A Yafi; Jacob Greenberg; Wayne J G Hellstrom; Hoang Minh Tue Nguyen; Georgios Hatzichristodoulou Journal: Sex Med Rev Date: 2018-11-30
Authors: M Capece; A Cocci; G Russo; G Cito; G Giubilei; G Cacciamani; G Garaffa; M Falcone; M Timpano; G Tasso; F Sessa; R Campi; F Di Maida; T Cai; G Morelli; B Giammusso; P Verze; A Palmieri; D Ralph; V Mirone; N Mondaini Journal: Andrology Date: 2018-05-07 Impact factor: 3.842
Authors: Hoang Minh Tue Nguyen; James Anaissie; Kenneth J DeLay; Faysal A Yafi; Suresh C Sikka; Wayne J G Hellstrom Journal: J Sex Med Date: 2017-09-02 Impact factor: 3.802
Authors: John P Mulhall; Steven D Creech; Stephen A Boorjian; Sam Ghaly; Edward D Kim; Ayham Moty; Rodney Davis; Wayne Hellstrom Journal: J Urol Date: 2004-06 Impact factor: 7.450
Authors: Andrea Cocci; Gianmartin Cito; Daniele Urzì; Andrea Minervini; Fabrizio Di Maida; Francesco Sessa; Andrea Mari; Riccardo Campi; Marco Falcone; Marco Capece; Girolamo Morelli; Giovanni Cacciamani; Michele Rizzo; Chiara Polito; Bruno Giammusso; Giuseppe Morgia; Paolo Verze; Andrea Salonia; Tommaso Cai; Vincenzo Mirone; Nicola Mondaini; Giorgio Ivan Russo Journal: J Sex Med Date: 2018-09-20 Impact factor: 3.802
Authors: Fabrizio Di Maida; Gianmartin Cito; Luca Lambertini; Francesca Valastro; Girolamo Morelli; Andrea Mari; Marco Carini; Andrea Minervini; Andrea Cocci Journal: World J Mens Health Date: 2020-07-08 Impact factor: 5.400
Authors: Andrea Cocci; Fabrizio Di Maida; Giorgio Ivan Russo; Marina Di Mauro; Gianmartin Cito; Marco Falcone; Andrea Minervini; Giovanni Cacciamani; Riccardo Campi; Andrea Mari; Francesco Sessa; Nicola Mondaini Journal: World J Mens Health Date: 2019-05-29 Impact factor: 5.400
Authors: Esther Garcia Rojo; Borja García Gómez; Rocio Santos-Pérez de la Blanca; Celeste Manfredi; Manuel Alonso Isa; José Medina Polo; Alfredo Rodríguez Antolín; Javier Romero Otero Journal: Asian J Androl Date: 2021 May-Jun Impact factor: 3.285